Last updated on December 2018

An Observational Study of Kadcyla Safety in Breast Cancer

Brief description of study

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 3,000 patients who are to receive Kadcyla (trastuzumab emtansine). Patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with trastuzumab and a taxane, and administered Kadcyla infusion at physician's discretion will be registered for this surveillance in Korea. Patients will be asked to provide informed consent; data will be collected by electronic Case Report Forms for approximately 6 years.

Clinical Study Identifier: NCT02305641

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML29629 ...

Chonnam National University Hwasun Hospital
Jeollanam-do, Korea, Republic of
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.